The Rise of VEGFxPD-(L)1 Multispecifics Report Summary
Following the release of standout data for ivonescimab and surge in recent deals between major biopharma such as Summit Therapeutics and Pfizer clinical collaboration, we have analysed the emergence of VEGFxPD-(L)1 multispecifics.
With exclusive data from Beacon, this review contains:
- Insights into the potential of VEGFxPD-(L)1 multispecifics becoming the new standard of care in lung cancer
- Analysis of the combination therapies that are being evaluated in VEGFxPD-(L)1 clinical trials
- An overview of the VEGFxPD-(L)1 licensing deals between major biopharma companies
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
